Katarina Luptakova
Chief Tech/Sci/R&D Officer bij XILIO THERAPEUTICS, INC.
Vermogen: - $ op 31-03-2024
Profiel
Katarina Luptakova is currently the Chief Medical Officer at Xilio Therapeutics, Inc. She previously worked as the Senior Medical Director at Tesaro, Inc. and as the Vice President-Clinical Development at Constellation Pharmaceuticals, Inc. She holds a doctorate degree from the University of Commenius.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
XILIO THERAPEUTICS INC
-.--% | 01-01-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Katarina Luptakova
| Bedrijven | Functie | Begin |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-10-2022 |
Eerdere bekende functies van Katarina Luptakova
| Bedrijven | Functie | Einde |
|---|---|---|
| TESARO INC | Chief Tech/Sci/R&D Officer | - |
| CONSTELLATION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Opleiding van Katarina Luptakova
| University of Commenius | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| XILIO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
